Injective Surges 17% on ETF Staking Update and Phantom Integration

Key Facts

1Injective price surged over 17% driven by institutional momentum and ecosystem developments.

221Shares filed an S-1 update for its Injective ETF, outlining a potential staking allocation of 40%–60% of the fund's INJ holdings.

In a move reflecting growing institutional interest in alternative digital assets, the Injective (INJ) token recorded a significant surge of over 17%. According to reports, this momentum was driven by regulatory updates and ecosystem expansions, specifically as 21Shares filed an S-1 update for its proposed Injective ETF. The filing outlines a strategic plan to allocate between 40% and 60% of the fund's INJ holdings to staking, potentially enhancing the product's appeal to institutional investors seeking additional yield.

Alongside regulatory progress, Injective strengthened its technical footprint through integration with the Phantom wallet, a leading gateway in the Solana ecosystem, facilitating easier management and trading of INJ assets. Per market data, this integration aims to lower barriers to entry for the Injective network and broaden its user base. Furthermore, the proposed ETF filing named BNY Mellon as administrator and custodian, with plans to list on the Nasdaq exchange under the ticker TINJ.

Looking ahead, the bullish trajectory for INJ remains closely tied to further progress in regulatory approvals for spot ETFs. Based on data as of September 19, 2026, while specific closing price levels are unavailable in the current snapshot, the qualitative trend remains positive. Traders should monitor subsequent SEC updates regarding the filing, as the upcoming economic calendar does not feature direct crypto-related catalysts within the next seven days.